Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.34 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.34 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102366 | 0.92 | LPAR5 (0.37) | LPAR5LPAR1LPAR4LPAR2LPAR3 | |
| SCHEMBL8752656 | 0.86 | LPAR5 (0.38) | LPAR5LPAR1LPAR4LPAR2LPAR3 | |
| SCHEMBL12333935 | 0.85 | LPAR5 (0.40) | LPAR5LPAR1LPAR4LPAR2LPAR3 | |
| SCHEMBL2126511 | 0.75 | SMN1; SMN2 (0.43) | LPAR5LPAR1LPAR4LPAR2LPAR3 | |
| SCHEMBL13112850 | 0.73 | PLA2G2A (0.42) | LPAR5LPAR1LPAR4LPAR2LPAR3 | |
| SCHEMBL8752670 | 0.72 | MAPT (0.32) | — | |
| SCHEMBL24909871 | 0.70 | PGK1 (0.32) | PGK1PGK2 | |
| SCHEMBL13931409 | 0.69 | — | — | |
| SCHEMBL8752659 | 0.69 | — | — | |
| SCHEMBL15545751 | 0.69 | CYP3A4 (0.35) | PGK1PGK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153608-B2 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | IDERA PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110150863-A1 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | IDERA PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150863-A1 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | NT5C2, ENTPD5, NT5E | LPAR5 408/4885LPAR1 1368/4885LPAR4 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.